Skyline Ventures
VC Fund
Palo Alto, United States
Skyline Ventures is a VC fund in Palo Alto focused on Biotechnology and Health Care. Skyline Ventures, formed in 1997, is a nationally-known venture capital firm that specializes in investing in outstanding product-focused healthcare companies. Their areas of expertise include small molecule and protein therapeutics; medical devices; diagnostics; and technologies that facilitate drug discovery and life science research.They allhave MD or PhD degrees, and hands-on operating experience in various start-up healthcare companies that later went public. As a result, they are known for the value they offer their companies, as board members and shareholders. They are also known for being fundamental, extremely patient investors.The days when momentum investing drove the public biotechnology markets are long gone, and they are glad that they are. The public markets demand data, not dreams. As a result, it is data that drives their decision process. In considering a new investment, they focus on whether there is adequate proof of principle to believe that the company's products will work.In therapeutics, for example, they look closely at whether the biochemistry, animal models and any human data make it more probable than average that the product will eventually prove to have an important therapeutic benefit. The size of the potential market and the quality of the management or founding team are critical in their evaluation as well.Skyline Ventures are value and return driven, more than driven by the stage of the investment. Most often they lead or co-lead a company's first or second institutional venture round, but have previously helped found companies and invested in PIPEs and leveraged buyouts.In October 2007, they completed raising Skyline V, which has $350 million in committed capital. They have approximately $800 million under management. They target investments of $15-35 million per portfolio company over the life of the company.
- Total investments:
- 77
- Last investment:
- Lead investor:
- 23%
- Fund size:
- $172M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Skyline Ventures invests in
Stages Skyline Ventures invests in
Countries Skyline Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Eric M Gordon
|
|||
John Freund
|
|||
Investment Focus
Industry
- Biotechnology 29 (38%)
- Health Care 26 (34%)
- Medical 23 (30%)
- Pharmaceutical 12 (16%)
- Medical Device 8 (10%)
Stage
- Series B 21 (27%)
- Series A 13 (17%)
- Series C 11 (14%)
- Series D 9 (12%)
- Funding Round 9 (12%)
Country
- United States 40 (52%)
- China 2 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Eric M Gordon
Founder & Partner
|
Founder & Partner | Total investments: 0 | Find email | |
|
John Freund
Founder & Managing Director
|
Founder & Managing Director | Total investments: 3 | Find email | |
Stephen J. Hoffman
Managing Director
|
Managing Director | Total investments: 16 | Find email | |
Yasunori Kaneko
Managing Director
|
Managing Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CIARRA
|
CIARRA APPLIANCES has been focusing on the kitchen appliance market in Europe and America since its inception. CIARRA will not stop: making full use of the influence of online brands and starting to deploy offline, combining online and offline channels, and gradually building a complete sales operation system to achieve cost and service advantages.Build a multi-level logistics distribution system to create efficient logistics. Focusing on the needs of different scenarios in the kitchen, we continue to expand categories and continue to expand the growth margin of CIARRA. | Series A / Sep 02, 2022 | |
Muse Technology
|
Muse Technology is a one-stop online furniture retail and e-commerce platform for the purchase of indoor furniture. | $10M / Series A / Nov 08, 2021 | |
Sutro Biopharma
|
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. | $85.4M / Series E / Jul 26, 2018 | |
Dicerna Pharmaceuticals
|
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The productcandidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.The company was founded in 2007 and is headquartered in Lexington, Massachusetts. | $70M / Post-IPO Debt / Mar 30, 2017 | |
SI-BONE
|
SI-BONE provides a titanium implant fixation system for the sacroiliac joint using the patented iFuseTM implant with a cannulated delivery system. When compared to the standard SI open fusion procedure, the iFuse implant procedure is less invasive, much quicker and much simpler to achieve fixation of the sacroiliac joint. | $26M / Jun 17, 2016 | |
|
SI-BONE
|
SI-BONE provides a titanium implant fixation system for the sacroiliac joint using the patented iFuseTM implant with a cannulated delivery system. When compared to the standard SI open fusion procedure, the iFuse implant procedure is less invasive, much quicker and much simpler to achieve fixation of the sacroiliac joint. | $21M / May 26, 2015 | |
Collegium Pharmaceutical
|
Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focusedon building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform. | $50M / Private Equity / Mar 10, 2015 | |
Proteon Therapeutics
|
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $45M / Series D / May 16, 2014 | |
|
SI-BONE
|
SI-BONE provides a titanium implant fixation system for the sacroiliac joint using the patented iFuseTM implant with a cannulated delivery system. When compared to the standard SI open fusion procedure, the iFuse implant procedure is less invasive, much quicker and much simpler to achieve fixation of the sacroiliac joint. | $33M / Apr 28, 2014 | |
|
Sutro Biopharma
|
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. | $26M / Series D / Dec 11, 2013 | |
| See all 77 investments → | |||
Co-Investors
Three Arch Partners
11 deals together
TVM Capital
11 deals together
Intersouth Partners
10 deals together
InterWest Partners
8 deals together
Montreux Equity Partners
8 deals together
Abingworth
7 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Skyline Ventures invest in?
Skyline Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 77 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Skyline Ventures?
Public channels for Skyline Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Skyline Ventures?
The team at Skyline Ventures includes Eric M Gordon (Founder & Partner), John Freund (Founder & Managing Director) and Stephen J. Hoffman (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
